S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

CASI Pharmaceuticals Stock Forecast, Price & News

-0.03 (-3.35%)
(As of 12/1/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.27 million shs
Average Volume
1.63 million shs
Market Capitalization
$120.92 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Pharmaceuticals logo

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.


CASI Pharmaceuticals Earnings Preview
November 13, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$15.14 million
Book Value
$0.66 per share


Net Income
$-48.29 million
Net Margins
Pretax Margin




Free Float
Market Cap
$120.92 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.40 out of 5 stars

Medical Sector

179th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

28th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

Is CASI Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI Pharmaceuticals stock.
View analyst ratings for CASI Pharmaceuticals
or view top-rated stocks.

How has CASI Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CASI shares have decreased by 46.9% and is now trading at $0.8650.
View which stocks have been most impacted by COVID-19

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for CASI Pharmaceuticals

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Friday, November, 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The biotechnology company had revenue of $8.11 million for the quarter, compared to analyst estimates of $7.77 million. CASI Pharmaceuticals had a negative net margin of 175.18% and a negative trailing twelve-month return on equity of 49.87%. During the same quarter in the prior year, the company posted ($0.14) earnings per share.
View CASI Pharmaceuticals' earnings history

What guidance has CASI Pharmaceuticals issued on next quarter's earnings?

CASI Pharmaceuticals issued an update on its FY 2021 earnings guidance on Friday, November, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.25 M-, compared to the consensus revenue estimate of $28.58 million.

What price target have analysts set for CASI?

3 analysts have issued 12-month target prices for CASI Pharmaceuticals' shares. Their forecasts range from $3.80 to $4.00. On average, they anticipate CASI Pharmaceuticals' share price to reach $3.93 in the next year. This suggests a possible upside of 354.7% from the stock's current price.
View analysts' price targets for CASI Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:
  • Wei-Wu He, Executive Chairman & Chief Executive Officer (LinkedIn Profile)
  • Wei Zhang, President
  • Alexander A. Zukiwski, Chief Medical Officer
  • James E. Goldschmidt, Senior Vice President-Business Development

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.16%), BlackRock Inc. (0.83%), Marshall Wace LLP (0.68%), Geode Capital Management LLC (0.68%), Millennium Management LLC (0.58%) and Cubist Systematic Strategies LLC (0.16%). Company insiders that own CASI Pharmaceuticals stock include Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends for CASI Pharmaceuticals

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, and BlackRock Inc..
View insider buying and selling activity for CASI Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Geode Capital Management LLC, Cubist Systematic Strategies LLC, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Goldman Sachs Group Inc., Citadel Advisors LLC, and UBS Group AG. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Larry Zhang, Weihao Xu, and Wei-Wu He.
View insider buying and selling activity for CASI Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $0.87.

How much money does CASI Pharmaceuticals make?

CASI Pharmaceuticals has a market capitalization of $120.92 million and generates $15.14 million in revenue each year. The biotechnology company earns $-48.29 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does CASI Pharmaceuticals have?

CASI Pharmaceuticals employs 144 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.

Where are CASI Pharmaceuticals' headquarters?

CASI Pharmaceuticals is headquartered at 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 864-2600, via email at [email protected], or via fax at 301-315-2437.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.